Alexion
Rare disease clinical trials: the urgent need for patients to be heard
May 22, 2024Alexion, Pharmafocus, Rare Diseases, clinical trials, feature
Ahead of Clinical Trials Day, Soraya Bekkali, from Alexion, AstraZeneca Rare Disease, highlights the urgent need to elevate patients’ voices …
AstraZeneca’s Alexion partners with Pfizer for rare disease therapies
July 28, 2023Research and Development Alexion, AstraZeneca, Pfizer, Rare Diseases, genomics, rare disease
Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and licence agreement with Pfizer. The …
Alexion pauses Phase III ULTOMIRIS COVID-19 trial enrolment
January 15, 2021Medical Communications Alexion, COVID-19
Alexion has paused further enrolment in the global Phase III study of ULTOMIRIS (ravulizumab-cwvz) in adult COVID-19 patients requiring mechanical …
AstraZeneca to buy Alexion in $39 billion deal
December 14, 2020Sales and Marketing Alexion, AstraZeneca, merger
British-Swedish AstraZeneca is set to acquire American biopharmaceutical company Alexion for $39 billion, in a move that will see a …
Alexion’s Ondexxya approved for NHS Scotland to treat uncontrolled and life-threatening bleeds
September 9, 2020Research and Development, Sales and Marketing Alexion, NHS, Ondexxya, Scotland, nhs scotland
The Scottish Medicines Consortium (SMC) has given its recommendation to Alexion’s Ondexxya (andexanet alfa) to routine use on NHS Scotland …
Portola Pharmaceuticals to merge with Alexion in $1.41bn cash deal
May 6, 2020Research and Development, Sales and Marketing Alexion, Portola Pharmaceuticals, pharma
Alexion has announced it is to acquire Boston-based blood disorder specialist Portola Pharmaceuticals in a transaction to the value of …
Apellis therapy outflanks Alexion’s Soliris in head-to-head paroxysmal nocturnal haemoglobinuria
January 8, 2020Research and Development Alexion, Appelis, pegcetacoplan, pharma, soliris
Apellis Pharmaceuticals has revealed new Phase 3 demonstrating that its targeted C3 inhibitor pegcetacoplan met its primary endpoint and outclassed …
FDA approves Alexion’s Ultomiris in atypical haemolytic uremic syndrome for adults and children
October 21, 2019Sales and Marketing Alexion, FDA, Ultomiris, pharma, rare disease
The FDA has moved to expand the existing label for Alexion’s Ultomiris (ravulizumab-cwvz) to include the treatment of atypical haemolytic …
Alexion to acquire Achillion Pharma for $930 million
October 16, 2019Research and Development, Sales and Marketing Alexion, achillion, merger, pharma
Alexion has revealed it has signed a definitive agreement to acquire Achillion Pharmaceuticals in a deal valued at $930 million, …
Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder
August 28, 2019Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris
Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …
European approval for Alexion’s Ultomiris in rare blood disease
July 4, 2019Sales and Marketing Alexion, Europe, Ultomiris, paroxysmal nocturnal haemoglobinuria
Alexion has received marketing authorisation from the European Commission for its long-acting C5 complement inhibitor Ultomiris (ravulizumab) in the treatment …
Alexion’s Soliris almost entirely eliminates relapses in rare neuromyelitis optica spectrum disorder
September 26, 2018Research and Development Alexion, neuromyelitis optica spectrum disorder, pharma, rare disease, soliris
Alexion has revealed new Phase 3 findings for Soliris (eculizumab), showing the drug met its primary endpoint in the treatment …
Alexion goes back to roots with Complement deal
June 11, 2018Manufacturing and Production, Sales and Marketing Alexion, biotech, drugs, pharma, pharmaceutical, soliris
Alexion has made a lot of money from investing in the science behind complement inhibitors – C5 inhibitor, Soliris, has …
Investigational Alexion drug proves non-inferior to Soliris in rare blood disease
April 27, 2018Medical Communications, Research and Development Alexion, paroxysmal nocturnal haemoglobinuria, pharma, soliris
Alexion has lifted the curtain on new data for its C5 complement inhibitor ALXN1210, demonstrating its non-inferiority to another of …
Alexion $855m portfolio boost after Wilson Therapeutics buyout
April 11, 2018Research and Development, Sales and Marketing Alexion, Wilson's Therapeutics, Wilson's disease, biotech, drugs, pharma, pharmaceutical
Alexion Pharmaceuticals is badly in need of alternative revenue streams to Soliris, its mega-blockbuster that could start to face competition …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
